2-propynyl adenosine analogs having A.sub.2A agonist activity and compositions thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7214665
APP PUB NO 20030186926A1
SERIAL NO

10263379

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides compounds having the following general formula (I): ##STR00001## wherein X, R.sup.1, R.sup.2, R.sup.7 and Z are as described here.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
UNIVERSITY OF VIRGINIACHARLOTTESVILLE, VA392

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Figler, Robert Alan Earlysville, VA 10 130
Linden, Joel M Charlottesville, VA 36 720
Macdonald, Timothy L Charlottesville, VA 61 497
Murphree, Lauren Jean Earlysville, VA 3 36
Rieger, Jayson M Charlottesville, VA 49 594
Sullivan, Gail W Charlottesville, VA 26 650

Cited Art Landscape

Patent Info (Count) # Cites Year
 
NOVARTIS CORPORATION (1)
4968697 2-substituted adenosine 5'-carboxamides as antihypertensive agents 60 1989
 
AMERICAN HOME PRODUCTS CORPORATION (1)
5124455 Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents 75 1990
 
MERCK FROSST CANADA LTD. (2)
6020339 Aryl furan derivatives as PDE IV inhibitors 43 1998
6034089 Aryl thiophene derivatives as PDE IV inhibitors 39 1998
 
UNIVERSITY OF ROCHESTER, ROCHESTER, NEW YORK 14627, A NOT-FOR-PROFIT CORP. OF NEW YORK (1)
4938949 Treatment of damaged bone marrow and dosage units therefor 326 1988
 
SCHERING CORPORATION (1)
5593975 Adenosine derivatives having A.sub.2 agonist activity 59 1995
 
BIC CORPORATION (1)
6332771 Utility lighter 14 1999
 
TOA EIYO LTD. (1)
* 6936596 Adenosine derivatives and use thereof 13 2001
 
PFIZER INC. (5)
6326359 Adenosine A2A receptor agonists as antiinflammatory agents 33 1999
6350735 Purine derivatives 15 2000
6525032 Purine derivatives 27 2001
6624158 Purine derivatives 14 2001
2003/0013,675 Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases 31 2002
 
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (2)
5298508 Irreversible inhibitors of adenosine receptors 33 1992
6545002 Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors 28 2000
 
PUREF, LLC (1)
6004945 Use of adenosine compounds to relieve pain 27 1995
 
BIOCHEM PHARMA INC. (2)
5756706 Processes for the diastereoselective synthesis of nucleoside analogues 48 1994
5696254 Processes for the diastereoselective synthesis of nucleoside analogues 49 1994
 
Glaxo Wellcome Inc. (1)
5776940 Phenylxanthine derivatives 27 1997
 
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (1)
5668139 A1 adenosine receptor agonists and antagonists 22 1995
 
NEW YORK UNIVERSITY (2)
5932558 Adenosine receptor agonists for the promotion of wound healing 29 1996
6020321 Adenosine receptor agonists for the promotion of wound healing 25 1999
 
The University of Patent Foundation (1)
5854081 Stable expression of human A.sub.2B adenosine receptors, and assays employing the same 38 1996
 
UNIVERSITY OF VIRGINIA (14)
4965271 Method of inhibiting the activity of leukocyte derived cytokines 74 1987
5096906 Method of inhibiting the activity of leukocyte derived cytokines 80 1990
5272153 Method of inhibiting the activity of leukocyte derived cytokines 42 1992
5877180 Method for treating inflammatory diseases with A.sub.2a adenosine receptor agonists 72 1994
6117878 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors 60 1998
6303619 Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors 30 1998
6060481 Method for improving insulin sensitivity using an adenosine receptor antagonist 26 1999
6322771 Induction of pharmacological stress with adenosine receptor agonists 47 1999
6448235 Method for treating restenosis with A2A adenosine receptor agonists 41 2000
6514949 Method compositions for treating the inflammatory response 41 2000
6531457 Methods and compositions for treating inflammatory response 33 2001
6670334 Method and compositions for treating the inflammatory response 32 2002
2006/0040,888 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity 12 2005
2006/0040,889 2-polycyclic propynyl adenosine analogs having A2A agonist activity 16 2005
 
ADERIS PHARMACEUTICALS, INC. (4)
5140015 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents 54 1990
5278150 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions 45 1992
RE36494 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents 23 1993
6339072 Compositions and methods for preventing restenosis following revascularization procedures 20 2001
 
ICOS CORPORATION (1)
5665754 Substituted pyrrolidines 50 1993
 
BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (1)
4665074 6-(polyfluoroalkoxyphenyl) pyridazinones, their compositions, synthesis and use 32 1985
 
CARDIOKINE, INC. (1)
5998386 Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue 45 1997
 
PATENT FOUNDATION, VIRGINIA, UNIVERSITY OF (1)
6232297 Methods and compositions for treating inflammatory response 30 1999
 
Item Development AB (1)
5731296 Selective vasodilation by continuous adenosine infusion 40 1993
 
AVENTIS PHARMACEUTICALS PRODUCTS INC. (2)
5364862 Compounds having antihypertensive and anti-ischemic properties 90 1992
5561134 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties 80 1994
 
PHARMACIA & UPJOHN SPA (1)
5593976 New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds 16 1995
 
Yamasa Corporation (1)
* 6387889 Medicinal compositions for treating eye diseases 19 2001
 
Burroughs Wellcome Co. (1)
4879296 Xanthine derivatives 50 1986
 
ANGELLO, PAUL S., 1858 PALISADES TERRACE DRIVE, LAKE OSWEGO, OREGON 97034 (1)
4824660 Method of determining the viability of tissue in an organism 34 1985
 
KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC (1)
5070877 Novel method of myocardial imaging 74 1989
 
Yamasa Shoyu Kabushiki Kaisha (2)
4956345 2-alkynyladenosines as antihypertensive agents 59 1988
5189027 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases 57 1991
 
TEVA PHARMACEUTICAL INDUSTRIES LTD. (1)
5565462 Composition for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative 26 1994
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
TROVIS PHARMACEUTICALS, LLC (8)
8293720 R agonists 1 2008
* 2009/0162,292 SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS 10 2008
* 2009/0181,920 INTRATHECAL TREATMENT OF NEUROPATHIC PAIN WITH A2AR AGONISTS 64 2009
7888329 R agonists 6 2009
* 2009/0280,059 SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS 8 2009
* 8263762 R agonists 1 2010
* 2011/0003,766 ALKOXY-CARBONYL-AMINO-ALKYNYL-ADENOSINE COMPOUNDS AND DERIVATIVES THEREOF AS A2AR AGONISTS 0 2010
* 8222228 Substituted aryl piperidinylalkynyladenosines as A2AR agonists 0 2010
 
UNIVERSITY OF VIRGINIA (23)
* 2009/0170,803 ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES 6 2003
7427606 Method to reduce inflammatory response in transplanted tissue 11 2004
* 2005/0182,018 Method to reduce inflammatory response in transplanted tissue 3 2004
* 7605143 agonist activity 10 2005
7576069 2-polycyclic propynyl adenosine analogs having A2A agonist activity 14 2005
7442687 2-polycyclic propynyl adenosine analogs having A2A agonist activity 7 2005
* 2006/0040,889 2-polycyclic propynyl adenosine analogs having A2A agonist activity 16 2005
* 2006/0040,888 2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity 12 2005
7378400 Method to reduce an inflammatory response from arthritis 14 2005
* 2006/0100,169 Method to reduce an inflammatory response from arthritis 1 2005
8178509 Method to treat sickle cell disease 0 2007
7737127 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof 5 2007
* 2007/0232,559 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF 9 2007
* 2007/0265,440 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY RESPONSE 6 2007
8188063 modulators to treat spinal cord injury 2 2007
* 2008/0064,653 USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY 13 2007
* 2009/0162,282 SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS 6 2008
7989431 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity 3 2009
7875595 2-polycyclic propynyl adenosine analogs having A2A agonist activity 4 2009
* 2009/0253,647 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY 6 2009
8158604 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof 0 2010
* 2010/0152,127 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF 4 2010
* 2011/0136,755 2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY 3 2011
 
Lewis and Clark Pharmaceuticals, LLC (1)
9067963 A agonists 0 2013
 
Zalicus, Inc. (3)
* 2009/0053,168 TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS 2 2008
* 2009/0047,243 COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS 2 2008
* 2010/0009,934 BETA ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS 6 2009
 
GLAXO GROUP LIMITED (2)
* 7985740 Purine derivatives as agonists of the adenosine A2A receptor 0 2006
* 2008/0214,581 Purine Derivatives as Agonists of the Adenosine A2a Receptor 12 2006
 
AKITA UNIVERSITY SCHOOL OF MEDICINE (1)
* 2008/0027,022 METHOD TO TREAT GASTRIC LESIONS 18 2007
 
PGXHEALTH, LLC (1)
8058259 R agonists 4 2008
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 8, 2018
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00